During infections, the immune system needs to distinguish foreign antigens that are expressed by invading bacteria and viruses from self-antigens that are expressed by cells of the body.

Among the 13 CAR-T therapeutics that have received regulatory approval are Gilead’s Yescarta and Immuneel Therapeutics’ ...

New research shows how a specially trained population of immune cells keeps the peace by preventing other immune cells from attacking their own. The study provides a better understanding of immune ...

This therapy targets multiple tumor-specific antigens, offering improved treatment precision for blood cancer patients, and ...

In an early-stage clinical trial, the therapy nearly doubled the expected survival time of young patients. Still, experts ...

Researchers and pediatric neurosurgeons at the University of Pittsburgh School of Medicine and UPMC Children's Hospital of ...

Malabar Cancer Centre (MCC) in Kannur successfully implements CAR T-cell therapy, a groundbreaking treatment for blood cancer ...

Bi-Specific 3rd Generation CAR T therapy is a revolutionary advancement in cellular immunotherapy, primarily used to treat blood cancers such as leukemia, lymphoma, and multiple myeloma.

The Car-T cell therapy was tested on patients with B-cell leukaemia and lymphoma - rare types of blood cancers - that affect the bone marrow and the lymphatic system.

Data incorporated for this study were collected from 9 centers in the UK focused on third-line and beyond chimeric antigen ...

Cellogen Therapeutics’ CAR T cell technology introduces a bi-specific approach to cancer immunotherapy. Unlike conventional ...